Morgan Stanley Appeals for Reconsideration of Stress Capital Buffer

Morgan Stanley (MS) is appealing to the Federal Reserve for a downward adjustment to its Stress Capital Buffer (SCB), with a decision anticipated by September 30. Currently, MS has the highest SCB among tested banks at 6%, but expects a reduction to 5.1% (effective October 2025) and its Common Equity Tier 1 (CET1) requirement to decrease to 12.6% from the current 15%. A successful appeal, mirroring recent revisions for Goldman Sachs and Wells Fargo, would enhance Morgan Stanley's capital flexibility, potentially impacting its ability to deploy capital for investments or shareholder returns.

Analysis

Morgan Stanley is actively petitioning the Federal Reserve for a downward revision of its Stress Capital Buffer (SCB), with a definitive ruling anticipated by September 30. The bank currently operates with an SCB of 6.0%, the highest among the institutions tested, which imposes significant capital constraints. A successful appeal is crucial, as the bank's own projections, based on recent stress test outcomes, indicate an expected future SCB of 5.1% and a corresponding drop in its Common Equity Tier 1 (CET1) requirement to 12.6%. This regulatory development holds material importance, as a lower SCB directly enhances a bank's capital flexibility for shareholder distributions and investments. The appeal is supported by precedent, as both Goldman Sachs and Wells Fargo recently secured modest downward revisions to their 2024 SCB requirements. Despite this potential positive catalyst, Morgan Stanley's shares have slightly underperformed the industry over the past six months, gaining 16.5% compared to the industry's 17.1% growth, suggesting the market may not have fully priced in a favorable outcome.

Key Decisions for Investors

• Investors should monitor the Federal Reserve's decision on Morgan Stanley's Stress Capital Buffer by September 30, as a downward revision is a key potential catalyst for improving the bank's capital efficiency and unlocking value.
• A successful appeal could justify a bullish position by freeing up capital for enhanced shareholder returns, while a rejection would maintain a key capital constraint relative to peers.
• Given the stock's recent slight underperformance against the industry (16.5% vs 17.1% gain), a favorable regulatory outcome could act as a specific catalyst to help close this performance gap.